THELMA Therapeutics Co., Ltd. operates as a biopharmaceutical company in South Korea and internationally. The company develops TLM-01, a non-alcoholic steatohepatitis drug; TLM-02, an antiviral agent for COVID-19; TLM-03/TLM-04, an anticancer drug for solid and blood cancer; and TLM-05, a liver cancer drug. It also offers radioembolization and brachytherapy devices for the cancer treatments. The company was formerly known as Medipartner Biotechnology. Co., Ltd. THELMA Therapeutics Co., Ltd. was founded in 1981 and is headquartered in Seoul, South Korea.
Research context
THELMA Therapeutics Co., Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
THELMA Therapeutics Co., Ltd is currently in a long term downtrend where the price is trading 9.5% below its 200 day moving average.
From a valuation standpoint, the stock is 642.5% more expensive than other stocks from the Industrials sector with a price to sales ratio of 7.0.
THELMA Therapeutics Co., Ltd's total revenue rose by 0.9% to $2B since the same quarter in the previous year.
Its net income has increased by 32.3% to $-8B since the same quarter in the previous year.
Finally, its free cash flow grew by 54.8% to $-2B since the same quarter in the previous year.
Based on the above factors, THELMA Therapeutics Co., Ltd gets an overall score of 3/5.